RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rallybio Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.35+0.07 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $94.80M
- P/E (TTM)
- 2.1
- Dividend yield
- –
Rallybio Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Reportable Segment | $858.00K | $636.00K | – | 100.0% | +34.9% |
| Reporting Segment | – | $636.00K | $0 | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Collaboration and license revenue | $858.00K | $636.00K | $0 | 100.0% | +34.9% |
| License | $800.00K | $600.00K | – | 93.2% | +33.3% |
By region
From the segment and revenue-disaggregation notes of Rallybio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.